Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment)

References

• TandonRNasrallahHAKeshavanMSSchizophrenia, “just the facts” 4. Clinical features and conceptualizationSchizophr Res20091101–312319328655
   PubMed Web of Science ®Google Scholar
• HallerCSPadmanabhanJLLizanoPTorousJKeshavanMRecent advances in understanding schizophreniaF1000Prime Rep201465725184047
   PubMedGoogle Scholar
• TandonRNasrallahHAKeshavanMSSchizophrenia, “just the facts” 5. Treatment and prevention. Past, present, and futureSchizophr Res20101221–312320655178
   PubMed Web of Science ®Google Scholar
• KapurSMamoDHalf a century of antipsychotics and still a central role for dopamine D2 receptorsProg Neuropsychopharmacol Biol Psychiatry20032771081109014642968
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcEvoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353121209122316172203
   PubMed Web of Science ®Google Scholar
• GrossGWickeKDrescherKUDopamine D(3) receptor antagonism – still a therapeutic option for the treatment of schizophreniaNaunyn Schmiedebergs Arch Pharmacol2013386215516623128852
   PubMed Web of Science ®Google Scholar
• MillanMJGressierHBroccoMThe dopamine D3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in ratsEur J Pharmacol19973213R7R99085054
   PubMed Web of Science ®Google Scholar
• GyertyánISághyKLaszyJSubnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. Behavioural characterisation of RG-15Naunyn Schmiedebergs Arch Pharmacol2008378552953918548231
   PubMed Web of Science ®Google Scholar
• MillanMJDekeyneARivetJMDubuffetTLavielleGBroccoMS33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626J Pharmacol Exp Ther200029331063107310869411
   PubMed Web of Science ®Google Scholar
• LaszyJLaszlovszkyIGyertyánIDopamine D3 receptor antagonists improve the learning performance in memory-impaired ratsPsychopharmacology (Berl)2005179356757515619116
   PubMed Web of Science ®Google Scholar
• MillanMJDi CaraBDekeyneASelective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysisJ Neurochem200710041047106117266737
   PubMed Web of Science ®Google Scholar
• LeggioGMMicaleVDragoFIncreased sensitivity to antidepressants of D3 dopamine receptor-deficient mice in the forced swim test (FST)Eur Neuropsychopharmacol200818427127717804207
   PubMed Web of Science ®Google Scholar
• GrossGDrescherKThe role of dopamine D(3) receptors in antipsychotic activity and cognitive functionsHandb Exp Pharmacol201221316721023027416
   PubMedGoogle Scholar
• KissBLaszlovszkyIHorváthASubnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. Neurochemical characterisation of RG-15Naunyn Schmiedebergs Arch Pharmacol2008378551552818551280
   PubMed Web of Science ®Google Scholar
• JoyceJNMillanMJDopamine D3 receptor antagonists as therapeutic agentsDrug Discov Today2005101391792515993811
   PubMed Web of Science ®Google Scholar
• KissBHorváthANémethyZCariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profileJ Pharmacol Exp Ther2010333132834020093397
   PubMed Web of Science ®Google Scholar
• KissBHortiFBobokACariprazine, a D3/D2 dopamine receptor partial agonist antipsychotic, displays greater D3 receptor occupancy in vivo compared with other antipsychoticsSchizophr Res2012136Suppl 1S190
   Google Scholar
• PappMGrucaPLason-TyburkiewiczMAdhamNKissBGyertyánIAttenuation of anhedonia by cariprazine in the chronic mild stress model of depressionBehav Pharmacol2014255–656757425083572
   PubMed Web of Science ®Google Scholar
• ZimniskyRChangGGyertyánIKissBAdhamNSchmaussCCariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mousePsychopharmacology (Berl)201322619110023079899
   PubMed Web of Science ®Google Scholar
• DurgamSStaraceALiDAn evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trialSchizophr Res20141522–345045724412468
   PubMed Web of Science ®Google Scholar
• KaneJMZukinSWangYEfficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trialJ Clin Psychopharmacol201535436737326075487
   PubMed Web of Science ®Google Scholar
• DurgamSCutlerAJLuKCariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase III randomized, double-blind, placebo- and active-controlled trialJ Clin Psychiatry
   Google Scholar
• DebelleMNémethGSzalaiECariprazine as monotherapy for the treatment of schizophrenia patients with predominant negative symptoms: a double-blind, active controlled trialEur Neuropsychopharmacol201525Suppl 2S510
   Google Scholar
• CitromeLCariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerabilityExpert Opin Drug Metab Toxicol20139219320623320989
   PubMed Web of Science ®Google Scholar
• MészárosGPKapásMBorsosMPharmacokinetics of RGH-188, a new dopamine D3/D2 antagonist/partial agonist atypical antipsychotic, in healthy subjectsEur Neuropsychopharmacol200717Suppl 4S451S452
   Google Scholar
• EreshefskyLAndorGGageAPhase I study of RGH-188 in schizophrenic patientsPoster presented at: the 161st Annual Meeting of the American Psychiatric AssociationMay 3–8; 2008Washington, DC
   Google Scholar
• MészárosGPÁgai-CsongorEKapásMSensitive LC-MS/MS methods for the quantification of RGH-188 and its active metabolites, desmethyl- and didesmethyl-RGH-188 in human plasma and urineJ Pharm Biomed Anal200848238839718242914
   PubMed Web of Science ®Google Scholar
• KaySRFiszbeinAOplerLAThe positive and negative syndrome scale (PANSS) for schizophreniaSchizophr Bull19871322612763616518
   PubMed Web of Science ®Google Scholar
• GuyWThe clinician global severity and impression scalesECDEU Assessment Manual for PsychopharmacologyRockville, MDNational Institute of Mental Health1976218222DHEW Publication 76-338
   Google Scholar
• PierreJMExtrapyramidal symptoms with atypical antipsychotics: incidence, prevention and managementDrug Saf200528319120815733025
   PubMed Web of Science ®Google Scholar
• WeberNSCowanDNMillikanAMNiebuhrDWPsychiatric and general medical conditions comorbid with schizophrenia in the National Hospital Discharge SurveyPsychiatr Serv20096081059106719648193
   PubMed Web of Science ®Google Scholar
• DurgamSEarleyWLiRLong-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a double-blind, placebo-controlled trialEur Neuropsychopharmacol201525Suppl 2S512S513
   PubMedGoogle Scholar